UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
29 mars 2021 08h30 HE
|
Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
23 mars 2021 09h00 HE
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22 mars 2021 21h00 HE
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22 mars 2021 08h30 HE
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
MAKO MEDICAL RELEASES LATEST COVID-19 VARIANT DATA
16 févr. 2021 11h39 HE
|
MAKO Medical
Raleigh, North Carolina, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, released new information regarding the company's...